Melane Sampson, Author at BioTuesdays

Developments

Japan approves SIGA’s antiviral for orthopoxvirus

SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan...

January 3, 2025

Executive Moves

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Grown Rogue (CSE:GRIN; OTC:GRUSF) has appointed Andrew Marchington as its chief financial officer (CFO) and corporate secretary, succeeding Ryan Kee effective January 1, 2025. Previously serving as senior vice president...

January 2, 2025

Executive Moves

Avalo names Jennifer Riley as CSO

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Jennifer Riley as chief strategy officer (CSO), a newly created role effective January 1, 2025. Ms. Riley will oversee corporate strategy, as well as...

January 2, 2025

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Executive Moves

Adicet appoints Julie Maltzman as CMO

Adicet Bio (NASDAQ:ACET) has appointed Julie Maltzman, MD, as chief medical officer (CMO), effective January 13, 2025. Adicet reports that Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure with...

December 18, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Feature

GRIN targeting rare pediatric neurological disorders with precision therapies

Closely held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

December 17, 2024

Developments

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...

December 16, 2024

Executive Moves

Jeb Ledell joins KalVista as COO

KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO). Mr. Ledell brings more than 20 years of leadership and operational excellence in the...

December 16, 2024

Developments

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...

December 16, 2024

Author - Melane Sampson

Japan approves SIGA’s antiviral for orthopoxvirus

Grown Rogue announces Andrew Marchington as CFO and corporate secretary

Avalo names Jennifer Riley as CSO

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Adicet appoints Julie Maltzman as CMO

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

GRIN targeting rare pediatric neurological disorders with precision therapies

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Jeb Ledell joins KalVista as COO

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

Subscribe